We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $268M
1-Year Est. Return 158.98%
This Fund
S&P 500
This Quarter Est. Return
+35.4%
1 Year Est. Return
+158.98%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$268M
AUM Growth
+$45.6M
Cap. Flow
+$18.2M
Cap. Flow %
6.78%
Top 10 Hldgs %
33.7%
Holding
508
New
146
Increased
78
Reduced
73
Closed
186

Top Buys

1
TSEM icon
Tower Semiconductor
TSEM
+$9.09M
2
LITE icon
Lumentum
LITE
+$8.24M
3
GLW icon
Corning
GLW
+$6.49M
4
INTC icon
Intel
INTC
+$5.94M
5
ALAB icon
Astera Labs
ALAB
+$4.77M

Top Sells

1
CNC icon
Centene
CNC
+$9.07M
2
MOH icon
Molina Healthcare
MOH
+$8.9M
3
ELV icon
Elevance Health
ELV
+$8.08M
4
BTSG icon
BrightSpring Health Services
BTSG
+$3.52M
5
TERN
Terns Pharmaceuticals
TERN
+$2.78M

Sector Composition

1 Technology 44.62%
2 Healthcare 29.67%
3 Financials 9.04%
4 Consumer Discretionary 3.92%
5 Energy 3.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
U icon
476
Unity
U
$12.7B
– –
-6,734
Closed -$297K
UNH icon
477
UnitedHealth
UNH
$387B
– –
-2,766
Closed -$913K
VIR icon
478
Vir Biotechnology
VIR
$1.59B
– –
-63,550
Closed -$506K
VKTX icon
479
PUT
Viking Therapeutics
VKTX
$4.31B
– –
-851
Closed -$52.5K
VNDA icon
480
CALL
Vanda Pharmaceuticals
VNDA
$327M
– –
-530
Closed -$57K
VOR icon
481
Vor Biopharma
VOR
$980M
– –
-10,798
Closed -$141K
VRDN icon
482
Viridian Therapeutics
VRDN
$1.99B
– –
-5,670
Closed -$176K
VTGN icon
483
CALL
VistaGen Therapeutics
VTGN
$9.4M
– –
-287
Closed -$3
VTYX
484
DELISTED
Ventyx Biosciences
VTYX
– –
-53,642
Closed -$484K
WVE icon
485
Wave Life Sciences
WVE
$1.12B
– –
-19,827
Closed -$337K
XBIT icon
486
XBiotech
XBIT
$69.2M
– –
-13,565
Closed -$32.4K
XGN icon
487
Exagen
XGN
$106M
– –
-13,230
Closed -$80.4K
XNTK icon
488
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.05B
– –
-669
Closed -$36.2K
XRAY icon
489
Dentsply Sirona
XRAY
$2.81B
– –
-8,605
Closed -$98.4K
ZYME icon
490
CALL
Zymeworks
ZYME
$1.78B
– –
-649
Closed -$359K
ZYME icon
491
PUT
Zymeworks
ZYME
$1.78B
– –
-57
Closed -$1
BTSG icon
492
BrightSpring Health Services
BTSG
$13.9B
– –
-93,897
Closed -$3.52M
BBOT
493
BridgeBio Oncology
BBOT
$686M
– –
-8,585
Closed -$107K
CTNM
494
Contineum Therapeutics
CTNM
$532M
– –
-13,853
Closed -$158K
PACS icon
495
PACS Group
PACS
$7.3B
– –
-26,940
Closed -$1.03M
BWLP icon
496
BW LPG
BWLP
$3.09B
– –
-43,398
Closed -$568K
VIK icon
497
Viking Holdings
VIK
$43.3B
– –
-14,773
Closed -$1.05M
BIOA
498
CALL
BioAge Labs
BIOA
$1.01B
– –
-61
Closed -$20.3K
TECX
499
CALL
Tectonic Therapeutic
TECX
$615M
– –
-229
Closed -$44.1K
ETHA
500
iShares Ethereum Trust ETF
ETHA
$5.09B
– –
-39,950
Closed -$896K
17 18 19
20
21

Similar funds

VC
VarCov Co Darien, Connecticut $268M AUM
AL
AIP LLC New York $268M AUM 40.4% 1-Year Est. Return
FC
Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return
NF
Nvest Financial Portsmouth, New Hampshire $268M AUM 22.87% 1-Year Est. Return
PF
Prosperitas Financial Valencia, California $268M AUM 32.64% 1-Year Est. Return
UI
Untitled Investments New York $269M AUM 11.35% 1-Year Est. Return
SSWM
Strait & Sound Wealth Management San Francisco, California $269M AUM 22.03% 1-Year Est. Return
AC
Applied Capital Little Rock, Arkansas $268M AUM 16.92% 1-Year Est. Return

Persistent Asset Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Persistent Asset Partners held 508 positions worth $268M, up 20% from $223M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Persistent Asset Partners deployed $18.2M of net new capital in Q1 2026, opening 146 new positions and adding to 78 existing holdings. Its largest new stake was Tower Semiconductor: 67,608 shares worth $11.9M.

By sector, the portfolio is most concentrated in Technology at 45% of assets, up from 14% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Terns Pharmaceuticals, an estimated $2.78M trimmed.

  • Persistent Asset Partners's largest Q1 2026 buy was Tower Semiconductor: 67,608 shares worth $11.9M.
  • Persistent Asset Partners added most to Lumentum in Q1 2026, an estimated $8.24M increase.
  • Persistent Asset Partners's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $2.78M.
  • Persistent Asset Partners fully exited Centene in Q1 2026, selling an estimated $9.07M.
  • Persistent Asset Partners's ten largest holdings make up 34% of its $268M portfolio in Q1 2026.
  • Persistent Asset Partners opened 146 new positions and closed 186 in Q1 2026.
  • Persistent Asset Partners's portfolio value rose 20% quarter-over-quarter to $268M.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.